Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Folotyn
(United States) [Available]Synonyms :
pralatrexate Â
Class :
Anticancer, antimetabolites, folate antagonists
Brand Name :
Folotyn
(United States) [Available]Synonyms :
pralatrexate Â
Class :
Anticancer, antimetabolites, folate antagonists
Dosage forms & Strengths Â
Intravenous solutionÂ
20 mg/ml Â
40 mg/2ml  Â
Lyophilized powder for solution  Â
200 mg/16ml Â
25 mg/2ml Â
Powder for solution Â
25 mg/vial Â
30
mg/m^2
Intravenous (IV)
once weekly for 6 – 7 weeks cycle; continue until unacceptable toxicity or disease progression.
15
mg/m^2
Intravenous (IV)
once weekly for 3 – 4 weeks cycle; continue until unacceptable toxicity or disease progression.
Dose Adjustments
Adjustment in case of renal impairment:
eGFR > 30 ml/minute/1.73m2: No dose adjustment needed
eGFR 15 to 30 ml/minute/1.73m2: reduce the dose to 15 mg/m2
Avoid the use of pralatrexate for patients with end-stage renal disease, including dialysis.
Discontinue the treatment in patients with grade 3 or 4 hepatotoxicity.
Not determined Â
Refer to adult dosingÂ
may enhance the serum concentration when combined with pralatrexate
may enhance the serum concentration when combined with pralatrexate
may enhance the serum concentration when combined with pralatrexate
may enhance the serum concentration when combined with pralatrexate
may enhance the serum concentration when combined with pralatrexate
trimetrexate may diminish the therapeutic effects of BCG vaccine
avoid the combination as it may increase nephrotoxicity
interaction with trimetrexate may diminish the therapeutic effects of the vaccine, avoid combination
take the vaccine at least 2 weeks prior to trimetrexate initiation to avoid interaction. The interaction may reduce the therapeutic effect of the vaccine
increases toxicities such as myelosuppression, renal toxicity, and GI toxicity
may enhance myelosuppressive toxicity of pralatrexate
high-risk for serious infections due to increasing immunosuppression
may increase toxic adverse effects of pralatrexate
increases serum concentration and toxic effect on GI, avoid the combination
increases serum concentration and toxic effect on GI, avoid the combination
increases serum concentration and toxic effect on GI, avoid the combination
interaction with NSAIDs may lead to increased toxicity such as myelosuppression, renal toxicity, and GI toxicity
interaction with NSAIDs may lead to increased toxicity such as myelosuppression, renal toxicity, and GI toxicity
interaction with NSAIDs may lead to increased toxicity such as myelosuppression, renal toxicity, and GI toxicity
increases the serum level of pralatrexate
interaction with NSAIDs may lead to increased toxicity such as myelosuppression, renal toxicity, and GI toxicity
interaction with NSAIDs may lead to increased toxicity such as myelosuppression, renal toxicity, and GI toxicity
interaction with NSAIDs may lead to increased toxicity such as myelosuppression, renal toxicity, and GI toxicity
interaction with NSAIDs may lead to increased toxicity such as myelosuppression, renal toxicity, and GI toxicity
interaction with NSAIDs may lead to increased toxicity such as myelosuppression, renal toxicity, and GI toxicity
interaction with NSAIDs may lead to increased toxicity such as myelosuppression, renal toxicity, and GI toxicity
interaction with NSAIDs may lead to increased toxicity such as myelosuppression, renal toxicity, and GI toxicity
avoid palifermin during pralatrexate therapy and before and after 24 hours of treatment
interaction with NSAIDs may lead to increased toxicity such as myelosuppression, renal toxicity, and GI toxicity
interaction with NSAIDs may lead to increased toxicity such as myelosuppression, renal toxicity, and GI toxicity
interaction with NSAIDs may lead to increased toxicity such as myelosuppression, renal toxicity, and GI toxicity
increase toxic adverse effects and immunosuppression
interaction with NSAIDs may lead to increased toxicity such as myelosuppression, renal toxicity, and GI toxicity
diminish the therapeutic effects of the vaccine
may enhance the concentration of serum when combined with OAT1/3 substrates
may enhance the risk of serious infection by increasing the immunosuppressive effect, avoid combination
may enhance the risk of serious infection by increasing the immunosuppressive effect, avoid combination
may enhance the risk of serious infection by increasing the immunosuppressive effect, avoid combination
may diminish the therapeutic effect of brincidofovir
may diminish the therapeutic effect of the covid-19 vaccine
combination may enhance the immunosuppressive effect and lead to serious infections
combination may enhance the immunosuppressive effect and lead to serious infections
combination may enhance the immunosuppressive effect and lead to serious infections
combination may enhance the immunosuppressive effect and lead to serious infections
myelosuppressive agents may enhance adverse myelosuppressive effects of Olaparib
pralatrexate may diminish the therapeutic effects of pidotimod
may enhance adverse myelosuppressive effects
may enhance adverse effects of pralatrexate
may reduce the therapeutic effect
may reduce the therapeutic effect
may reduce the therapeutic effect
pralatrexate: it may enhance the toxic effect of Anti-Inflammatory Agents
pralatrexate: it may enhance the toxic effect of Anti-Inflammatory Agents
aspirin, chlorpheniramine, and phenylephrine
pralatrexate: it may enhance the toxic effect of Anti-Inflammatory Agents
pralatrexate: it may enhance the toxic effect of Anti-Inflammatory Agents
pralatrexate: it may enhance the toxic effect of Anti-Inflammatory Agents
may increase the serum concentration of OAT1/3 substrates
may result in a significant increase in zavegepant exposure
may diminish the serum concentration of each other when combined
trimethoprim: they may enhance the serum concentration of pralatrexate
increase the metabolism of pralatrexate
increase the metabolism of pralatrexate
increase the metabolism of pralatrexate
Actions and Spectrum:Â Â
Pralatrexate is a type of folate analog, and they work by blocking dihydrofolate reductase synthetase. This double inhibition reduces production of essential molecules which depends on the transfer of single carbon atoms. Â
Frequency defined Â
>10%:Â Â Â
Fever Â
Night seats Â
Hypokalemia Â
Abdominal pain Â
Nausea Â
Vomiting Â
Weight loss Â
Mucositis Â
Myelosuppression Â
1%-10%Â Â
Alopecia Â
Dermatitis Â
Skin photosensitivity Â
Gastrointestinal ulcer Â
Pruritis Â
Leukopenia Â
Pancytopenia Â
Thrombocytopenia Â
Dizziness Â
Frequency not defined:Â Â
Hypotension Â
Black Box Warning:Â Â
None
Â
Contraindication/Caution:Â Â
Contraindications Â
Hypersensitivity Â
Breast-feeding Â
Cautions Â
Renal impairment Â
Hepatic impairment Â
Myelosuppression Â
Pregnancy Warnings:Â
Pregnancy category: N/AÂ
Lactation: Excretion of the drug into the human breast milk is unknownÂ
Pregnancy categories:Â
Category A: Satisfactory and well-controlled studies show no evidence of risk to the fetus in the first trimester or in the later trimester.Â
Category B: No evidence of risk to fetus found in animal reproduction studies and there are not enough studies on pregnant women.Â
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women.Â
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits.Â
Category X: Drugs listed in this category clearly outweigh risks over benefits. These category drugs should be prohibited for pregnant women.Â
Category N: There is no data available for the drug under this category.Â
Pharmacology:Â Â
Pralatrexate inhibits dihydrofolate reductase (DHFR) which disrupts RNA synthesis and DNA replication and induces apoptosis. It boasts higher intracellular concentration and prolonged retention within cells compared to methotrexate.Â
Pharmacodynamics:Â Â
Pralatrexate boasts higher intracellular concentration and prolonged retention within cells compared to methotrexate. It acts in the S-phase thus arresting cell growth and serves as an immunosuppressive agent. Â
Pharmacokinetics:Â Â
Limited information is available on ADME. Â
Â
Administration:Â Â
It is administered as an intravenous route. Â
Patient information leafletÂ
Generic Name:Â pralatrexateÂ
Pronunciation: PRA-la-trex-ate
Why do we use pralatrexate?Â
Pralatrexate is a chemotherapy drug indicated for the treatment of peripheral T-cell lymphoma (PTCL) and Cutaneous T Cell Lymphoma (CTCL).Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
